Cancer News and Research

Latest Cancer News and Research

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Simple lifestyle changes can reduce your cancer risk: Dana-Farber expert

Health care organizations from around the globe will come together on Saturday, Feb. 4 to promote cancer prevention as part of this year's World Cancer Day.

4 Feb 2012

UCSD Moores Cancer Center offers NovoTTF procedure for patients with GBM

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device - available only at clinical trial sites - is offering new hope to these patients.

4 Feb 2012

VuCOMP receives PMA for M-Vu CAD system

VuCOMP, Inc., developer of computer-aided detection (CAD) systems for automatic analysis of medical imagery, is pleased to announce premarket approval (PMA) of M-Vu, a cutting-edge CAD system for film mammography.

3 Feb 2012

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Majority of geriatric patients in German rehabilitation hospital have vitamin D deficiency

The great majority of geriatric patients in a German rehabilitation hospital were found to have vitamin D deficiency. Stefan Schilling presents his study results in this week's issue of Deutsches Ärzteblatt International.

3 Feb 2012

Worldwide malaria death figures - a gross underestimate, finds latest research

According to latest research malaria kills twice as many people every year as formerly believed, taking 1.2 million lives and causing the deaths not only of babies but also older children and adults.

3 Feb 2012

Is sugar as bad as alcohol and tobacco?

According to US health experts, sugar is as damaging and addictive as alcohol or tobacco and should be regulated. The University of California team suggests new policies such as taxes are needed to control soaring consumption of sugar and sweeteners. Prof Robert Lustig argues in the opinion piece called “The Toxic Truth About Sugar” in journal Nature for major shifts in public policy.

3 Feb 2012

Urine-based biomarkers may lead to development of test for high-risk prostate cancer

Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease.

3 Feb 2012

MD Anderson study defines value in health care

A team from The University of Texas MD Anderson Cancer Center is receiving a national award for a research article tackling a question vital to the future of health care with reform regulations looming, competition growing and costs rising.

3 Feb 2012

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.

3 Feb 2012

Strategies to minimize side effects of oxaliplatin in metastatic colon cancer

The drug oxaliplatin is a major reason the prognosis for metastatic colon cancer has gone from an expected survival of several months to a couple years. Unfortunately, the drug can also carry with it debilitating neurological side effects, which generally start as the sensation of pins and needles in fingers and toes and can leave patients unable to walk or dress independently.

3 Feb 2012

Pediatricians lead statewide effort to raise awareness about childhood vaccination

Two Saint Louis University pediatricians are leading a Missouri State Medical Association statewide effort to change the way doctors respond to parents' fears of vaccines, and to raise awareness about the importance of getting children vaccinated.

3 Feb 2012

Scientists identify molecular switch that controls ATF2's dual functions

The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanoma-the deadliest form of skin cancer-at some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies

3 Feb 2012

NCDB: Five-year survival rates higher among cancer patients treated in SCCA

Five-year survival rates among patients treated by Seattle Cancer Care Alliance for eight types of cancer are higher than for patients treated at other academic medical centers, as well as large and small community cancer centers nationwide, according to data compiled by the National Cancer Data Base (NCDB).

3 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

AHF calls for top to bottom shake-up of management at FDA

AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."

3 Feb 2012

Viewpoints: Censoring flu research; Assailing Komen's move to cut Planned Parenthood funding

In December, the National Science Advisory Board for Biosecurity made an unprecedented request: it asked the editors of the journals Nature and Science not to publish certain details in two papers describing experiments in which scientists created a highly transmissible form of the deadly H5N1 influenza virus. ... Such caution, though well intentioned, is misplaced.

3 Feb 2012

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment

3 Feb 2012

Uproar follows Komen-Planned Parenthood rift

Anti-abortion activists applaud the move, but many other women's health advocates are angered the well-known breast cancer advocacy group has opted against helping another prominent women's health organization.

3 Feb 2012